GlassScriptPhysician profile
Kelly Peppel
NPI 1003332040
$2,885.70
in general payments reported to CMS, 2019-2025
25 companies · $698 in 2025
The $698 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $778 · 2023: $428 · 2024: $348 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $589.34 | 2021-2025 | |
| Exeltis, USA INC. | $285.53 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $260.08 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $241.53 | 2021 | |
| Astellas Pharma US INC | $233.03 | 2022-2025 | Veozah |
| Abbvie INC. | $226.19 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.14 | 2021-2025 | |
| Biogen, INC. | $119.82 | 2025 | Zurzuvae |
| Pfizer INC. | $102.22 | 2023-2025 | |
| Sage Therapeutics, LLC | $92.07 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $90.80 | 2021-2024 | Twirla |
| Organon LLC | $78.31 | 2024-2025 | Nexplanon, Jada System |
| Virtus Pharmaceuticals LLC | $57.80 | 2021-2022 | |
| Avion Pharmaceuticals | $48.64 | 2021-2022 | |
| Therapeuticsmd, INC. | $36.26 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $35.18 | 2022 | |
| Novo Nordisk INC | $32.14 | 2022-2023 | Wegovy |
| Myovant Sciences INC. | $28.50 | 2021-2022 | |
| Exact Sciences Corporation | $27.28 | 2025 | The Cologuard Plus Collection Kit |
| Millicent US INC | $25.38 | 2025 | Intrarosa, Femlyv |
| Supernus Pharmaceuticals, INC. | $23.77 | 2025 | Qelbree |
| Aspira Women'S Health INC | $18.77 | 2022 | |
| Sumitomo Pharma America, INC. | $17.47 | 2025 | Myfembree |
| Biohaven Pharmaceutical Holding Company LTD. | $16.52 | 2022 | |
| Coopersurgical, INC. | $15.93 | 2023 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Peppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.